Introduction
============

Studies using machine learning methods gained popularity in medical researches in recent years. Machine learning methods integrate computer-based algorithms into data analysis to find similar patterns among different samples. The ultimate goal aims at using multiple variables to predict a specific outcome in a particular cohort. There are two types of machine learning algorithms in general: supervised and unsupervised machine learning. In supervised machine learning, both of the predictors and outcome are known; but in unsupervised machine learning, only the predictors are fed into the algorithm.

The most common type of tumors originated in the sellar region included pituitary neoplasm, craniopharyngioma, meningioma and chordoma, which overall takes more than 10--15% of tumors in the central nervous system ([@bib1]). Other non-tumorous sellar region diseases include Rathke's cyst, hypophysitis, hypopituitarism and all the complications due to the treatment of these diseases ([@bib2]). Machine learning may help to build a more reliable aided diagnostic tool for neuroradiologists and neuropathologists. Better prediction of clinical outcomes in these patients may provide better clinical decision support for either neuroendocrinologists or neurosurgeons. While on the other hand, machine learning methods present a particular challenge because of the complexity in model training and testing. The reproducibility of scientific research has always been of critical importance, which also applies in machine learning studies ([@bib3]). With the expansion of machine learning in medical studies, the applications in real clinical decision making are booming, which requires both robustness and generalizability ([@bib4], [@bib5]).

This systematic review aims to compile the current literature on sellar region diseases that utilized different machine learning methods and analyze the reporting items regarding cohort selection, model building and model explanation. Unlike traditional statistical methods, risks of bias and confounding are not the main question of interest in machine learning studies. How to assess the quality of these studies remains unsolved, and a reporting guideline was not available for these studies to follow. This review presents a quality assessment tool and proposes a checklist of reporting items for studies built on machine learning methods.

Methods
=======

Literature for this review was identified by searching PubMed and Web of Science from the date of the first available article to December 1, 2018. The keywords containing 'machine learning' or the algorithms of machine learning were queried with the combination of keywords containing sellar region diseases (Supplementary Table 1, see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article). The search was limited to studies published in English. References in published reviews were manually screened for possible inclusions. The study adheres to the PRISMA guideline, and the checklist was provided in Supplementary Table 2.

Studies were included if they evaluated machine learning algorithms (logistic regression with regulation, linear discriminant analysis, k means, k nearest neighbor, cluster analysis, support vector machine, decision tree-based models and neural networks) for application in prediction of disease originated in the sellar region (both tumorous and non-tumorous diseases). Exclusion criteria were lack of full-text or animal studies.

Data obtained from each study were publication characterizes (first author's last name, publication time), cohort selection (sample size, diagnosis), predictors (variables fed into the machine learning models), outcomes (the outcomes as well as the controls, including the distributions between them), model selection (models used in the study, including platforms, packages and parameters), statistics for model performance (methods to evaluated the model, the mean and the variance) and model explanation (any explanation on how important of each predictors and proposed clinical application). Supplements in each study were also reviewed if available.

Quantitative synthesis was inappropriate due to the heterogeneity in outcomes. Summary of included studies was listed in a table and using a narrative approach. The proposed quality assessment ([Table 1](#tbl1){ref-type="table"}) of each study consists of five categories: unmet need (limits in current non-machine-learning approach), reproducibility (feature engineering methods, platforms/packages, hyperparameters), robustness (valid methods to overcome over-fit, the stability of results), generalizability (external data validation) and clinical significance (predictors explanation and suggested clinical use). A quality assessment table was provided by listing 'yes' or 'no' of corresponding items in each category. Table 1Quality assessment of machine learning studies.CategoriesItemsDescriptionReportedUnmet needLimits in current non-machine-learning approachLow diagnostic accuracy, low human-level prediction accuracy or prolonged diagnostic procedureYes/noReproducibilityFeature engineering methodsHow features were generated before model trainingYes/noPlatforms/packagesBoth platforms and packages should be reportedYes/noHyperparametersAll hyperparameters which are needed for study replicationYes/noRobustnessValid methods to overcome over-fitLeave-one-out or k-fold cross-validation or bootstrapYes/noThe stability of resultsCalculated variation in the validation statisticsYes/noGeneralizabilityExternal data validationValidation in settings different from the research frameworkYes/noClinical significancePredictors explanationExplanation of the importance of each predictorYes/noSuggested clinical useProposed possible applications in clinical careYes/no

To provide a clear picture of how to perform a machine learning study, the workflow of a machine learning study was summarized, and notations of terms used in these machine learning studies were provided. The recommended reporting items were also provided based on the results.

Results
=======

After scrutinizing the titles and abstracts generated by the searching strategy, 31 articles left for full-text screening, in which 13 studies were excluded: one study not in English, two duplicated studies, four conference abstracts without full-text and six studies without outcomes in sellar region diseases. Three studies used the same image database such that only the latest published study was included. At last, this systematic review included 16 studies ([@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21]) ([Table 2](#tbl2){ref-type="table"}), with the diagnosis of general pituitary neoplasms, acromegaly, Cushing's disease, craniopharyngioma and growth hormone deficiency. More than half of the studies were published in the recent 2 years. Table 2Summary of studies on sellar region disease using machine learning methods.Cohort selectionPredictorsOutcomesModels (parameters)Performance statisticsSample sizeDiagnosisOutcomes and controlsDistributionDiscriminationCV methodVariation in validationLearned-Miller 2006 (6)49AcromegalyParameters from 3D shape of faceAcromegaly/healthy24:25SVM (linear or quadratic kernel)Acc: 85.7%LOOCVNAKitajima 2009 (7)43Sellar massAge and 9 MRI featuresPituitary adenoma/craniopharyngioma/Rathke's cyst20:11:12NN (FC(7)\*1)AUC: 0.990LOOCVNALalys 2011 (8)500Pituitary adenomaFeatures in surgical imagesSix surgical phases: nasal incision/retract/tumor removal/column replacement/suture/nose compressNASVM (linear kernel), HMMAcc: 87.6%10-fold CV[s.d.]{.smallcaps}: 2.4%Hu 2012 (9)68Pituitary adenoma9 serum proteinsNFPA healthy34:34Decision tree (Gini index)Sen: 82.4%\
Spe: 82.4%10-fold CVNASteiner 2012 (10)15Pituitary adenomaSpectrum from histologyGH+/GH−/non-tumor cells1000:1000:1000k means (k = 10), LDAAcc: 85.3%LOOCV[s.d.]{.smallcaps}: 10.5%Calligaris 2015 (11)45Pituitary adenomaProtein signature in mass spectrometry from histologyACTH pituitary tumor/GH pituitary tumor/PRL pituitary tumor/pituitary gland6:9:9:6SVMSen: 83.0%\
Spe: 93.0%NANAPaul 2017 (12)233Brain tumorsPixels in MRI imagesMeningioma/glioma/pituitary tumor208:492:289CNN ((Cov(64)-Max)\*2 + FC(800)\*2), NN, SVMAcc: 94.0%5-fold CV[s.d.]{.smallcaps}: 4.5%Kong 2018 (13)1123AcromegalyFeatures in photosAcromegaly/healthy527:596EnsembleAcc: 95.5%NANAZhang 2018 (14)112Pituitary adenomaFeatures in MRI imagesNull cell adenoma/other subtypes46:66SVM (radial kernel)AUC:0.804\
Acc: 81.1%BootstrapNAMurray 2018 (15)124Growth hormone deficiencyAge, sex, IGF1, gene expressionsGrowth hormone deficiency/healthy98:26RFAUC:0.990Out-of-bag (3-fold CV)NAYang 2018 (16)168CraniopharyngiomaExpression levels of signature genesCraniopharyngioma/other brain or brain tumor samples24:144SVM (radial kernel)AUC:0.850NANAHollon 2018 (17)400Pituitary adenoma26 patient's characteristicsPoor early postoperative outcome/good124:276Elastic net, NB, SVM, RFAcc: 87.0%NANAStaartjes 2018 (18)140Pituitary adenomapatient characteristics, MRI featuresGross-total resection/not95:45NN (FC(5)\*NA)AUC: 0.96\
Acc: 90.9%5-fold CV without holdout[s.d.]{.smallcaps}:0.08%Kocak 2018 (19)47AcromegalyFeatures in MRI imagesResponse to somatostatin analogs/resistant24:23k-NN (k = 5)Acc: 85.1%\
AUC: 0.84710-fold CV[s.d.]{.smallcaps}: 1.5%Ortea 2018 (20)30Growth hormone deficiencyThree serum proteinsGrowth hormone deficiency/healthy15:15RF, SVMAcc: 100%\
AUC: 1.000BootstrapNASmyczynska 2018 (21)272Growth hormone deficiency with GH treatmentPatient characteristics, GH level, IGF-1 level, GH doseHeight change after GH treatment0.66 ± 0.57NN (FC(2)\*1)RMSE: 0.267NANA[^1]

The scheme of a machine learning study was summarized in [Fig. 1](#fig1){ref-type="fig"}. The process can be categorized into four stages when developing a prediction model. The first step is to bring out the clinical question, which is summarized as 'predicting Outcome using Predictors in a Cohort'. A study should choose the appropriate outcome, predictors and the data source. The data are then pre-processed, which can involve data coding, transformations, imputation and dimension reduction. The training step means how the model (algorithm) finds patterns from the features to match the outcome variable. The trained model should be validated (both internally and externally). Finally, models are explained, and possible clinical applications are provided. The notations of terms used in these machine learning studies were described in [Table 3](#tbl3){ref-type="table"}.Figure 1The scheme of a machine learning study. The process can be categorized into four steps: a good clinical question; pre-processed data; training and validation of the model and significance in clinical applications. Table 3Notations of special machine learning terms.TermsExplanationsUnsupervised learningA subgroup of machine leaning models with the purpose of finding similarities among samples where no outcomes are availableSupervised learningA subgroup of machine leaning models with both predictors and outcomes, and the purpose is to learn the mapping function from the predictors to the outcomesFeaturePredictors in a machine learning algorithmCategorizationTransforming a continuous variable into a categorical variableOne-hot encodingUsing a vector (all the elements of the vector are 0 except one) to re-code a categorical variableStandardizationRescale data to a specific range, e.g., dividing by mean or dividing by standard deviationNormalizationTransforming unnormalized data into normalized data, e.g., logarithm transformationOver-fitThe established model corresponds too exactly to the training dataset, and may therefore fail to predict future unseen observationsImputationAssigning the value of a missing data, e.g., using the mean of the existing dataDimension reductionRepresenting the original data with lesser dimensionsTrainingThe learning process of the data pattern by a modelLASSOLeast Absolute Shrinkage and Selection Operator: A regression analysis method that performs both variable selection and regularizationSVMSupport Vector Machine: Finding the best hyperplane to separate data in a high dimensional spaceNaïve BayesA simple probabilistic classifier based on Bayes' theoremkNNk Nearest Neighbor: Classification of a sample according to the distance to other samples in the multidimensional spaceNeural networkA family of models inspired by biological neural networksTreeA tree-like graph model of decisions and their possible consequencesEnsembleCombining several different models, calculating predictions from these models and then those predictions are used as weighted inputs into another regression model for the ultimate predictionParametersCoefficients of a model formula that need to be learned from the dataHyperparametersAll the configuration variables of a model which are often set manually by the practitionerValidationCalculating performance of a trained model in a separated datasetDiscriminationThe ability of a model to separate individuals in multiple classesCalibrationHow well a model's predicted probabilities concur with the actual probabilitiesCross-validationFirst, the data is partitioned into k (5 or 10) equally sized parts randomly with one part as the validation dataset and others as the training dataset. This process is repeated for k times with each of the subsamples used exactly once as the validation datasetLeave-one-outLeaving one sample out each time and training the model on the remaining samples. The process is repeated multiple times till all the samples are "leave-outed" onceBootstrappingRandomly sampled data from the whole original data (patients can be sampled multiple times) can be used to create new data. Training and validation are based on the new data, and the resampling process is repeated multiple timesRobustThe stability of a model in cross-validation or in sensitivity analysisFeature importanceHow much the accuracy decreases when the feature is excluded

Sample size in these studies varied from tens to thousands. The majority of the studies ([@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib20]) (76.5%) used the diagnosis of a specific disease as the outcome, only four studies ([@bib17], [@bib18], [@bib19], [@bib21]) tested on the treatment outcome. In the diagnostic studies, three studies ([@bib7], [@bib12], [@bib14]) used image features to categorize magnetic resonance images (MRIs), two ([@bib6], [@bib13]) used face photos to predict acromegaly, two ([@bib15], [@bib20]) predicted growth home deficiency using serum proteins, two ([@bib10], [@bib11]) used histological spectrum to predict histology diagnosis, one ([@bib9]) used serum proteins to predict pituitary adenoma and one ([@bib8]) predicted surgical phase using videos. In studies on treatment outcomes, one study ([@bib17]) predicted poor early postoperative outcome, one ([@bib18]) predicted gross-total resection, one ([@bib19]) predicted response to somatostatin analogs and one ([@bib21]) predicted growth after growth hormone treatment. All the outcomes were either dichotomized or categorical outcomes except one in the continuous form ([@bib21]).

Most of the studies (87.5%) arbitrarily chose one or two machine learning models without arguing the reasons. One study ([@bib13]) chose ensemble models by combining the decisions from multiple models to improve the overall performance. One study ([@bib17]) compared several models and chose the one with the best performance. With regard to validation methods, five studies ([@bib8], [@bib9], [@bib12], [@bib15], [@bib19]) used k-fold cross-validation, two studies ([@bib14], [@bib20]) used bootstrap and three studies ([@bib6], [@bib7], [@bib10]) used leave-one-out cross-validation. One study ([@bib18]) used cross-validation but without holdout and five studies ([@bib11], [@bib13], [@bib16], [@bib17], [@bib21]) did not report the validation method. In studies reporting validation methods, only five ([@bib8], [@bib10], [@bib12], [@bib18], [@bib19]) reported the variation of the validation statistics.

In the quality assessment ([Table 4](#tbl4){ref-type="table"}), limits in current non-machine-learning approach were mentioned in most of the studies. During the model training process, only two studies ([@bib6], [@bib17]) did not provide how the data were transformed into a way that can be fed into the algorithm. But nearly half the studies (43.8%) did not offer the program or the platform for model training and roughly half (43.8%) did not provide hyperparameters which are necessary for the training process. As mentioned above, 62.5% of the studies provided a valid method to combat over-fitting, but only five reported variations in the validation statistics. Only one study ([@bib16]) validated the algorithm in an external database. Though only four studies ([@bib15], [@bib17], [@bib18], [@bib21]) reported how to interpret the predictors, most studies (68.8%) suggested possible clinical application of the developed machine learning algorithm. Table 4Quality assessment of machine learning studies in sellar region disease.Unmet needReproducibilityRobustnessGeneralizabilityClinical significanceLimits in current non-machine-learning approachFeature engineeringPlatforms, packagesHyperparametersValid methods for over-fittingStability of resultsExternal data validationPredictors explanationSuggested clinical useLearned-Miller 2006 (6)YesNoYesNoYesNoNoNoYesKitajima 2009 (7)YesYesNoYesYesNoNoNoYesLalys 2011 (8)NoYesNoYesYesYesNoNoYesHu 2012 (9)NoNAYesYesYesNoNoNoYesSteiner 2012 (10)YesYesNoYesYesYesNoNoYesCalligaris 2015 (11)YesNANoNoNoNoNoNoYesPaul 2017 (12)YesYesNoYesYesYesNoNoNoKong 2018 (13)YesYesNoYesNoNoNoNoYesZhang 2018 (14)YesYesYesNoYesNoNoNoYesMurray 2018 (15)YesYesYesNoYesNoNoYesYesYang 2018 (16)YesYesYesYesNoNoYesNoNoHollon 2018 (17)NoNoYesNoNoNoNoYesNoStaartjes 2018 (18)YesYesYesNoNoYesNoYesYesKocak 2018 (19)YesYesYesYesYesYesNoNoNoOrtea 2018 (20)YesNAYesNoYesNoNoNoYesSmyczynska 2018 (21)YesYesNoYesNoNoNoYesNo[^2]

Based on the results, several recommended reporting items for a machine learning study were proposed ([Table 5](#tbl5){ref-type="table"}). Reporting of the background should include results by human intelligence and a summarized research question. In the methods part, it is recommended to report the diagnosis of the cohort; locations and period of the included patients; how the control group was determined; all the variables as predictors; the data coding, data transformation methods; missing data imputation methods; any censoring data. The methods part should also include the reason for choosing a specific model; the platform and the package for model building (recommended in Supplementary Table 3) and all the hyperparameters in the model if applicable. Reporting of the results should include the rate of binary outcome or the distribution of categorical or continuous outcome; the appropriate validation statistic based on the clinical question; the 95% confidence interval by cross-validation or bootstrap and whether an external validation was obtained. Reporting of the discussion should include the reason if arbitrarily chosen cut-off value; the clinical meaning of the discrimination or calibration statistics; explanation of the model (provide coefficients or feature importance if possible); discussion on how the model will be integrated into clinical care. Table 5A proposed reporting checklist of future studies using machine learning.Reporting of background should include Results of human intelligence or non-machine-learning approach A summarized research questionReporting of method should include Diagnoses of the cohort Locations and time span of the patients included How the control group was determined All the variables as predictors Data coding and data transformation methods Missing data imputation methods Any censoring data The reason for choosing a specific model The platform and the package for model building All the hyperparameters in the model if applicableReporting of results should include The rate of binary outcome or the distribution of categorical or continuous outcome The appropriate validation statistic based on the clinical question 95% confidence interval of validation statistic by cross-validation or bootstrapping Whether an external validation was obtainedReporting of the discussion should include The reason if arbitrarily chosen cut-off value Clinical meaning of the discrimination or calibration statistics Explanation of the model (provide coefficients or feature importance if possible); Discussion on how the model will be integrated in clinical care

Discussion
==========

The review summarized studies on sellar region disease with machine learning methods about cohort selections, predictors, outcomes, model buildings and validation methods. A quality assessment tool was proposed in these aspects: unmet needs, reproducibility, robustness, generalizability and clinical significance. A reporting checklist from the introduction to the discussion was also provided for future studies.

Though machine learning methods have the potential advantage of increasing the prediction power, researchers should always focus on the clinical questions. The unmet needs in current practice either in diagnosis or in posttreatment prediction were the drivers for expanding the use of this new method. In particular cases, results of human-level intelligence ([@bib13]) should be tested in scenarios where the predictions are majorly dependent on clinicians' subjective judgments in current standard care, for example, in studies in predicting gross-total resection rate after pituitary adenoma surgery ([@bib18]). In both studies, human-level intelligence results by either physicians' judgment or conventional prediction technique were provided. In particular situations, if the diagnostic process needs too much human labor, it was also a good argument for the application of machine learning methods ([@bib22], [@bib23]).

In general, machine learning studies were retrospective observational studies, and the predictors were usually all the variables which have been recorded. On the other hand, features can be generated by transforming data already collected using specific methods (standardization, normalization, centralization) ([@bib24]). These methods should be reported in the method part for study replication. There were also a few feature selection methods ([@bib25]), and most of them were based on maximizing the validation statistics. But we should be bear in mind that feature selection can either improve the robustness or have the potential to harm the generalizability.

Unsupervised leaning models are usually not used in clinical studies, because the purpose of these approaches is to find similarities among samples where no outcomes are available, for example, genomic grouping. In selecting specific supervised machine learning algorithms, no common rules apply. Because there was no guarantee that a certain algorithm performs the best in all kind of data. In general, neural networks performs better than other models in image data, and tree-based models perform better in tabular data.

Platforms, packages, parameters and hyperparameters were other critical issues for study replication, but only half of the studies provided this information. Algorithms like logistic regression with regulation, linear discriminant analysis, k means and k nearest neighbor are relatively easy to implement and do not require many hyperparameters. Support vector machine, decision tree-based models and neural networks are more complicated and need tons of hyperparameters during training. Proper reporting was necessary for study replication using these models.

Leave-one-out holds one sample out each time and trains the model on the remaining samples. Similarly, k-fold cross-validation (k = 5 or 10 in general) holds 1/5th or 1/10th of the samples out each time and trains the model on the remaining samples ([@bib9], [@bib19], [@bib22]). Bootstrap samples patients from the whole original data randomly to create new data in which a model was trained, and the resampling process is repeated multiple times ([@bib14], [@bib20]). It was not recommended to randomly split the data into two parts (training and testing) because it may have a big chance to achieve a relatively 'good' testing data such that biasing the model performance to the better direction.

Calibration seems not so important in sellar region disease in this systematic review. When the research question is to predict the classification, it is not important whether the predicted probabilities deviate to the real probabilities because the goal is to discriminate the predicted values between the two classes. On the other hand, in situations when predicting the probability of a specific class (e.g. mortality risk) is important, the predicted probabilities should be calibrated to avoid deviating too much from the actual probabilities ([@bib26]). Calibration is usually measured by Hosmer--Lemeshow goodness-of-fit test or by calibration belt plotting the distribution of real probability versus the predicted probability ([@bib27]).

Generalizability is another major concern in machine learning studies. The population to be generalized should have similar characteristics distribution and outcome proportion. If a model is to be truly applied in the clinical setting, it should be validated in another database. Recent food drug administration approved aided diagnostic tool for diabetic retinopathy diagnosis, atrial fibrillation detection and other diseases all require validation in the external dataset ([@bib4]).

Sometimes clinicians want to know which factors drive the model for the prediction in the whole population or in a particular patient, which highlights the importance of model explanation. On the population level, this can be solved by looking at coefficients of each variable in logistic regressions or calculating feature importance in tree-based models or neural networks. But sometimes individual-level explanation may be more important, which necessitate the interpretation of each variable in each sample. This procedure can be calculated by SHAP score, which means the contribution of each variable to the final prediction value ([@bib28]). But both explanations only tell why the model performs like the way it functions, but not anything about how we can improve our clinical practice, which is one major limit in machine learning methods.

Clinical applications include multiple aspects. Developing a smartphone application for acromegaly detection may help to increase the diagnostic rate of acromegaly ([@bib13]). Using histological spectrum to differentiate different tumor types may help quicker and more accurate intra-operative diagnosis ([@bib11]). Predicting somatostatin analog sensitivity can guide future clinical trials by recruiting patients more sensitive to the medications ([@bib19]). Precise prediction of postoperative adverse events may help to alarm surgeons to pay more attention to those patients who have a higher likelihood of developing these events ([@bib17]). Web-based online real-time prediction can also help increase physician--physician or physician--patient communication ([@bib29]).

Although machine learning approach provided additional prediction power comparing to conventional regression models, several concerns in applying this approach were listed as follows: (1) the superiority of prediction power were not guaranteed in every case; (2) machine learning approach is more data consuming and time consuming, thus is less efficient than conventional models; (3) different platforms, different packages and multiple hyperparameters of machine learning approach restrict its replicability among different research groups. Current gaps of knowledge still exist in how to correctly explain the machine learning models either in the global level or in the individual level.

Conclusion
==========

Machine learning methods were used to predict diagnosis and posttreatment outcomes in sellar region diseases. Though most studies had substantial unmet needs and proposed possible clinical application, replicability robustness assessed by variations in the validation statistics and generalizability evaluated by the external database, were major limits in current studies. Population-level and individual-level predictors explanation are also directions for future improvements.
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[^1]: Acc, accuracy; ACTH, adrenocorticotropic hormone; AUC, area under curve; BoVW, bag-of-visual-word; CNN, convolutional neural network; Cov, convolutional layer; CV, cross-validation; FC, fully-connected neural network; GH, growth hormone; HMM, hidden Markov model; IGF1, insulin-like growth hormone 1; LDA, linear discriminant analysis; LOOCV, leave-one-out cross-validation; Max, max pooling layer; MRI, magnetic resonance image; NA, not available; NB, naïve Bayesian; NFPA, non-functional pituitary adenoma; NN, neural network; PRL, prolactin; RF, random forest; RMSE, root mean square error; [s.d.,]{.smallcaps} standard deviation; Sen, sensitivity; Spe, specificity; SVM, support vector machine.

[^2]: NA, no need.
